Co-delivery of paclitaxel and cyclosporine by a novel liposome-silica hybrid nano-carrier for anti-tumor therapy via oral route

Yaoxue Xuebao

Volumn 49, Issue 1, 2014, Pages 106-114

  Deng, Li ^a   Su, Ting Ting ^a   Huang, Xing Liang ^a   Wang, Ya Hua ^a   Li, Chong ^a  

^a SOUTHWEST UNIVERSITY   (China)

Author keywords

Antitumor; Co delivery of drug pairs; Liposome; Paclitaxel; Silica dioxide

Indexed keywords

CYCLOSPORIN; NANOCARRIER; PACLITAXEL; SILICON DIOXIDE; ANTINEOPLASTIC AGENT; DRUG CARRIER; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE;

ARTICLE; BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; HYBRID; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CANCER TRANSPLANTATION; CHEMISTRY; DRUG EFFECTS; FEMALE; MALE; MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZATION; RAT; SARCOMA 180; SPRAGUE DAWLEY RAT; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DRUG CARRIERS; FEMALE; LIPOSOMES; MALE; MICE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; P-GLYCOPROTEIN; PACLITAXEL; PARTICLE SIZE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SARCOMA 180; SILICON DIOXIDE; TUMOR BURDEN;

EID: 84896793328     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ganesh S, Iyer AK, Weiler J, et al. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer [J]. Mol Ther Nucl Acids, 2013, 2: e110.
2. Lee J, Gollahon L. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells [J]. Int J Oncol, 2013, 42: 839-847.
3. Liu Y, Lu WY. Recent advances in brain tumor-targeted nano-drug delivery systems [J]. Expert Opin Drug Deliv, 2012, 9: 671-686.
4. Huang SX, Shao K, Kuang YY, et al. Tumor targeting and microenvironment-responsive nanoparticles for gene delivery [J]. Biomaterials, 2013, 34: 5294-5302.
5. Yan ZQ, Wang F, Wen ZY, et al. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor [J]. J Control Release, 2012, 157: 118-125.
6. Park JH, Maltzahn G, Xu MJ, et al. Cooperative nanomaterial system to sensitize, target, and treat tumors [J]. Proc Natl Acad Sci USA, 2010, 107: 981-986.
7. Chen H, Pazicni S, Krett NL, et al. Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment [J]. Angew Chem Int Ed Engl, 2009, 48: 9295-9299.
8. Zhang YF, Wang JC, Bian DY, et al. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies [J]. Eur J Pharm Biopharm, 2010, 74: 467-473.
9. Sengupta S, Eavarone D, Capila I, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system [J]. Nature, 2005, 436: 568-572.
10. Timo L, Christophe J, Jens M, et al. Nanostructured silica materials as drug-delivery systems for doxorubicin: single molecule and cellular studies [J]. Nano Lett, 2009, 9: 2877-2883.
11. Zhang YZ, Wang JC, Bai XY, et al. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs [J]. Mol Pharm, 2012, 9: 505-513.
12. Pan LM, He QJ, Liu JN, et al. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles [J]. J Am Chem Soc, 2012, 134: 5722-5725.
13. Barbé C, Bartlett J, Kong L, et al. Silica particles: a novel drug-delivery system [J]. Adv Mater, 2004, 16: 1959-1966.
14. Begu S, Aubert-Pouessel A, Lerner DA, et al. Liposil, a promising composite material for drug storage and release [J]. J Control Release, 2007, 118: 1-6.
15. Qi JJ, Yue XL, Wang Y, et al. Encapsulation and release of doxorubicin form silica-coated liposome [J]. J Clin Rehab Tissue Eng Res, 2009, 13: 4185-4188.
16. Bégu S, Durand R, Lerner DA, et al. Preparation and characterization of siliceous material using liposomes as template [J]. Chem Commun, 2003, 7: 640-641.
17. Dwivedi N, Arunagirinathan MA, Sharma S, et al. Silica-coated liposomes for insulin delivery [J]. J Nanomaterials, 2010, doi: 10.1155/2010/652048.
18. Liu JW, Stace-Naughton A, Jiang XM, et al. Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles [J]. J Am Chem Soc, 2009, 131: 1354-1355.
19. Ashley CE, Carnes EC, Epler KE, et al. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers [J]. ACS Nano, 2012, 6: 2174-2188.
20. Li C, Deng L, Zhang Y, et al. Silica-coated ethosome as a novel oral delivery system for enhanced oral bioavailability of curcumin [J]. Acta Pharm Sin, 2012, 47: 1541-1547.
21. Li CC, Zhang ZH, Zhang YL, et al. In situ rat intestine absorption of paclitaxel-loaded solid lipid nanoparticles modified with cell-penetrating peptides [J]. Acta Pharm Sin, 2013, 48: 131-137.
22. Van Asperen J, Van Tellingen O, van der Valk MA, et al. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A [J]. Clin Cancer Res, 1998, 4: 2293-2297.
23. Chen DB, Yang TZ, Lü WL, et al. In vitro and in vivo study of two kinds long-circulating solid lipid nanoparticles containing paclitaxel [J]. Acta Pharm Sin, 2002, 37: 54-58.
24. Zhang HJ, Xu Q, Ma K, et al. Preparation of cyclosporine a nano-particle eye drops and its irritation to the eyes [J]. J Clin Rehab Tissue Eng Res, 2012, 16: 8018-8022.
25. Chen YP, Lu Y, Chen JM, et al. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt [J]. Int J Pharm, 2009, 376: 153-160.
26. Zhang ZQ, Tan B, Li Z, et al. Preparation of paclitaxel liposomes modified with mPEG-DSPE and its pharmacokinetics in rats [J]. Chin Pharm J, 2008, 43: 199-202.
27. He L, Wang GL, Zhang Q, et al. Studies on hypersensitivity and pharmacokinetis of paclitaxel microemulsion [J]. Acta Pharm Sin, 2003, 38: 227-230.
28. Shen SK, Kendall E, Oliver A, et al. Liposil-supported lipid bilayers as a hybrid platform for drug delivery [J]. Soft Matter, 2011, 7: 1001-1005.
29. Guo JX, Ping QN, Wu T. Transdermal delivery mechanisms of lecithin nanoparticles with cyclosporine A through mice skin [J]. Acta Pharm Sin, 2000, 35: 782-785.
30. Hu CMJ, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform [J]. Proc Natl Acad Sci USA, 2011, 108: 10980-10985.
31. Breedveld P, Beijnen JH, Schellens JH, et al. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs [J]. Trends Pharmacol Sci, 2006, 27: 17-24.
32. Joo KM, Park K, Kong DS, et al. Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor [J]. Oncol Rep, 2008, 19: 17-23.
33. Kong B, Seog JH, Graham LM, et al. Experimental considerations on the cytotoxicity of nanoparticles [J]. Nanomedicine (Lond), 2011, 6: 929-941.
34. Kumar R, Roy I, Ohulchanskyy TY, et al. Covalently dye-linked, surface-controlled, and bioconjugated organically modified silica nanoparticles as targeted probes for optical imaging [J]. ACS Nano, 2008, 2: 449-456.
35. Seetharam RN, Sridhar KR. Nanotoxicity: threat posed by naoparticles [J]. Curr Sci, 2006, 93: 769-770.
36. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects [J]. Adv Drug Deliv Rev, 2011, 63: 161-169.